Global Blood Therapeutics: Funding, Investors & Team (Sep 2026)
GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and headquartered in San Francisco, California.
Global Blood Therapeutics has raised $300M across 1 funding round on record, the most recent a Post-IPO Debt of $300M announced in Dec 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Global Blood Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2021.
Global Blood Therapeutics Funding Rounds
Global Blood Therapeutics Founders and Leadership Team
Contact details for the Global Blood Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Global Blood Therapeutics Funding Compared to Other Biotechnology Startups
Global Blood Therapeutics' latest round of $300M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Global Blood Therapeutics in Biotechnology and San Francisco
Companies Similar to Global Blood Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Global Blood Therapeutics Funding FAQs
What does Global Blood Therapeutics do?
GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and headquartered in San Francisco, California.
How much funding has Global Blood Therapeutics raised?
Global Blood Therapeutics has raised $300M across 1 round on record. The most recent is a Post-IPO Debt of $300M announced in Dec 2021.
When did Global Blood Therapeutics last raise funding?
Global Blood Therapeutics' most recent funding round on record is a Post-IPO Debt of $300M, announced in Dec 2021.
Who is the CEO of Global Blood Therapeutics?
Ted W. Love is listed as CEO at Global Blood Therapeutics.
Where is Global Blood Therapeutics headquartered?
Global Blood Therapeutics is based in San Francisco, California, United States.
How many employees does Global Blood Therapeutics have?
Global Blood Therapeutics is in the 251-500 employee band.
How does Global Blood Therapeutics' funding compare to other Biotechnology startups?
Global Blood Therapeutics' latest round of $300M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Global Blood Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Global Blood Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.